SIGMAR1 and amyotrophic lateral sclerosis: Treatment with proteasome inhibitor MG‐132, but not with lysosomal protease inhibitors E64d/pepstatin A, significantly increased the amount of ALS‐linked Sig1R variants in the cells (Fig 2C), suggesting their constitutive degradation via proteasomes.